
US FDA Approves GSK Lung Cancer Drug
The US FDA granted accelerated approval to GSKs neladalkib for advanced lung cancer. The once-daily oral therapy targets patients whose disease progressed on existing treatments following the Nuvalent acquisition.
Xurve View
Insights:
Xurve View

GSK PLC-SPON ADR secured accelerated United States FDA approval on Tuesday evening for neladalkib to treat advanced non-small cell lung cancer. The regulatory milestone follows the company's $10.6B acquisition of Nuvalent, marking its aggressive return to oncology. The once-daily oral therapy targets patients whose disease progressed after previous treatments, offering an alternative to chemotherapy.











